Register or Sign in to Save this opportunity, or Send an Inquiry.
Pulmonary Delivery of Cisplatin for Improved Treatment of Lung Cancer
Health Technologies at Strathclyde United Kingdom flag United Kingdom
Abstract ID:
Inhaled formulation of Cisplatin with reductions in dosage and frequency
Send an Inquiry


Lung cancer is the most common cancer in the world and is the leading cause of cancer death. There are 1.61 million new cases diagnosed worldwide every year (the highest incidence being in Scotland) and it has one of the lowest survival rates.  The main drugs used in the treatment of lung cancer are platinum-based cytotoxic drugs such as cisplatin. Cisplatin is poorly absorbed orally and only 0.1% of the dose reaches the lungs after intravenous administration, where it has a short residence time.  Cisplatin has poor solubility and renal toxicity is a major problem. Novel formulations with reduced toxicity compared to cisplatin solution and similar or better therapeutic efficacy are required.



We have developed candidates for an improved formulation of cisplatin that is given by inhalation. This has great potential to improve lung cancer treatment through improved efficacy along with reduced toxicity, compared with conventional intravenous cisplatin therapy.

Key Benefits

·         Given by inhalation

·         Reduction in drug dosage and frequency of toxic cisplatin

·         Platform technology can likely be used for other drugs

Markets and Application

·         Improved formulation of cisplatin for the treatment of lung cancer

·         Platform can be applied to other disease areas

Type of Business Relationship Sought

Contact is welcomed from organisations interested in developing, licensing or exploiting this technology

Last Updated Oct 2013
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE


Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833